 |
53 Diseases |  |
2 Trials |
|
2 Trials |  |
95 News |  |
| 12» |
- | iniparib (BSI 201) / Sanofi, Rubraca (rucaparib) / Pharma& Schweiz, Lynparza (olaparib) / Merck (MSD), AstraZeneca
Journal, PARP Biomarker: Affinity Chromatographic Method for Determining Drug-Protein Interaction with Enhanced Speed Than Typical Frontal Analysis. (Pubmed Central) - Oct 22, 2023
The method was high speed since it allowed simultaneous determination of binding parameters between two drugs and a protein with a smaller number of experiments to be performed. Such a feature made the method an attractive alternative for high-speed analysis of drug-protein interaction or the other bindings in a binary system.
- | iniparib (BSI 201) / Sanofi
Yes I think iniparib really shook up the whole PARP therapy space. (Twitter) - Mar 23, 2023
- || carboplatin / Generic mfg., iniparib (BSI 201) / Sanofi, gemcitabine / Generic mfg.
P2 data, Clinical Trial,Phase II, Journal, Combination therapy, BRCA Biomarker, PARP Biomarker: Phase II Trials of Iniparib (BSI-201) in Combination with Gemcitabine and Carboplatin in Patients with Recurrent Ovarian Cancer. (Pubmed Central) - Mar 21, 2023
P2
Given the subsequent lack of efficacy demonstrated for iniparib in breast cancer, these are studies of GC and demonstrate a higher than traditionally appreciated activity in patients with platinum-sensitive and -resistant recurrent ovarian cancer, especially in patients that harbor a BRCA mutation, resetting the benchmark for efficacy in phase II trials. (ClinicalTrials.gov Identifiers: NCT01033292 & NCT01033123).
- | Journal, PARP Biomarker, PD(L)-1 Biomarker, IO biomarker: Differential effects of poly(ADP ribose) polymerase inhibitor-based metronomic therapy on programmed death-ligand 1 and matrix-associated factors in human myeloid cells. (Pubmed Central) - Jan 12, 2023
We recently showed that while partial poly(ADP-ribose) polymerase (PARP)-1 inhibition with a low metronomic sub-half-maximal inhibitory concentration/dose (IC50) of olaparib provides superior protection against colon cancer in mice compared to complete inhibition by blocking the suppressive function of myeloid-derived suppressor cells (MDSCs) and synergizing with anti-program cell death (PD)-1-based immunotherapy...A sub-IC50 concentration of other clinically used PARPi (rucaparib, niraparib, and talazoparib) as well as the failed PARPi, iniparib, exerted similar effects...Thus, PARPi-based metronomic therapy may promote functional changes in myeloid cells that provide an additional rationale for combining it with immunotherapy. Our results also provide new opportunities for iniparib in cancer therapy.
- | iniparib (BSI 201) / Sanofi, Zejula (niraparib) / GSK, J&J, Takeda
Journal: Crystal structures of the catalytic domain of human PARP15 in complex with small molecule inhibitors. (Pubmed Central) - Aug 13, 2022
Here, we solved high-resolution crystal structures of the human PARP15 catalytic domain in complex with three marketed drugs of PARP inhibitors, which includes compounds 3-AB, iniparib and niraparib. The structures reported here contribute to our understanding of the ligand binding modes and structural features in the PARP15 catalytic domain, which can be employed to guide the rational design of selective inhibitors of PARPs.
- | iniparib (BSI 201) / Sanofi
Journal: Biodegradable Oxygen-producing Manganese-chelated Metal Organic Frameworks for Tumor-targeted Synergistic Chemo/photothermal/ photodynamic Therapy. (Pubmed Central) - Jan 28, 2022
Herein, to overcome tumor-associated hypoxia, and further achieve tumor-targeted synergistic chemotherapy/PDT/photothermal therapy (PTT), we have constructed a biodegradable oxygen-producing nanoplatform (named Ini@PM-HP), which was composed of the porous metal-organic framework (PCN-224(Mn)), the poly (ADP-ribose) polymerase (PARP) inhibitor (Iniparib), and the polydopamine-modified hyaluronic acid (HA-PDA)...STATEMENT OF SIGNIFICANCE: A delicately designed biodegradable oxygen-producing nanoplatform Ini@PM-HP is constructed to achieve combination therapy of solid tumors. Taking advantage of the active-targeting, PTT, enhanced PDT and PARPi, this nanotherapeutic approach successfully enables the combined chemo/photothermal/photodynamic therapy with great inhibition of solid tumors.
- || Lartruvo (olaratumab) / Eli Lilly, iniparib (BSI 201) / Sanofi
Clinical, Journal: Fooled by randomness. The misleading effect of treatment crossover in randomized trials of therapies with marginal treatment benefit. (Pubmed Central) - Jan 21, 2022
Taking advantage of the active-targeting, PTT, enhanced PDT and PARPi, this nanotherapeutic approach successfully enables the combined chemo/photothermal/photodynamic therapy with great inhibition of solid tumors. Crossover can bias clinical outcomes of randomized clinical trials by increasing the risk of both type I (false positive) and type II (false negative) error.To show how crossover can increase type I error, we provide computer simulation and review herein illustrative examples (iniparib, olaratumab) of recently reported RCTs that demonstrated false positive treatment efficacy signals due to crossover.The ethic issues associated to crossover are also discussed.
- | iniparib (BSI 201) / Sanofi
Journal, PARP Biomarker: CRISPR/Cas9-mediated mutagenesis at microhomologous regions of human mitochondrial genome. (Pubmed Central) - Jan 7, 2022
InDel mutagenesis was significantly improved by sgRNA multiplexing and a DSB repair inhibitor, iniparib, demonstrating the evidence of rewiring DSB repair status to manipulate mtDNA using CRISPR/Cas9. These findings would provide novel insights into mtDNA mutagenesis and mitochondrial gene therapy for diseases involving pathogenic mtDNA.
- docetaxel / Generic mfg.
Targeting Acetyl-CoA carboxylase in pre-clinical breast cancer models (Hall 1) - Oct 26, 2021 - Abstract #SABCS2021SABCS_1439;
It showed synergy with iniparib and another metabolic inhibitor (TEPP46). Targeting de novo fatty acid synthesis by inhibiting ACC is a promising therapeutic strategy.
- || iniparib (BSI 201) / Sanofi
Clinical: The Impact of Platinum-Containing Chemotherapies in Advanced Triple-Negative Breast Cancer: Meta-Analytical Approach to Evaluating Its Efficacy and Safety. (Pubmed Central) - Sep 19, 2021
Targeting de novo fatty acid synthesis by inhibiting ACC is a promising therapeutic strategy. Platinum-containing chemotherapy remains a highly recommended therapeutic regimen due to greater effectiveness and tolerance for patients with advanced TNBC.
- ||| iniparib (BSI 201) / Sanofi
Orphan drug: #TriActTherapeutics Announces #Iniparib Granted #OrphanDrugDesignation by the #FDA for Treatment of #MalignantGlioma https://t.co/h5Lq37RRdU (Twitter) - Jul 8, 2021
- || Zaltrap (ziv-aflibercept IV) / Sanofi, Regeneron
Biomarker, Clinical, Journal, PARP Biomarker: Construction and optimization of gene expression signatures for prediction of survival in two-arm clinical trials. (Pubmed Central) - Sep 5, 2020
Platinum-containing chemotherapy remains a highly recommended therapeutic regimen due to greater effectiveness and tolerance for patients with advanced TNBC. The tools presented here should be of general use for building and using predictive multivariate signatures in oncology and in other therapeutic areas.
- || iniparib (BSI 201) / Sanofi
Clinical, Review, Journal, BRCA Biomarker, PARP Biomarker: Mutations of BRCA2 in canine mammary tumors and their targeting potential in clinical therapy. (Pubmed Central) - Sep 4, 2020
Early investigations show tolerability of iniparib in dogs...Mutations in the canine BRCA2 gene have the potential to be exploited in clinical therapy through the usage of PARP inhibitors. However, further investigations are needed before introducing PARP inhibitors in veterinary clinical practice.
- || Tecentriq (atezolizumab) / Roche
Biomarker, Clinical, Journal, Tumor Mutational Burden, PARP Biomarker, PD(L)-1 Biomarker, IO Biomarker: Tumor immune microenvironment and genomic evolution in a patient with metastatic triple negative breast cancer and a complete response to atezolizumab. (Pubmed Central) - Jul 16, 2020
P1
This case report describes the evolution of TiME and TNBC molecular subtypes/genomics over time with sequential therapies in a TNBC patient with a CR to atezolizumab monotherapy. These data suggest the TiME is pliable and may be manipulated to maximize response to immunotherapy (NCT01375842, https://clinicaltrials.gov/ct2/show/NCT01375842?term=NCT01375842&rank=1 ).
- | Journal, PARP Biomarker, PD(L)-1 Biomarker, IO Biomarker: ADP ribose polymerase inhibitors for treating non-small cell lung cancer: new additions to the pharmacotherapeutic armamentarium. (Pubmed Central) - Jul 7, 2020
In fact, the activity of these drugs would not be based only on direct cytotoxic action, but also on the modification of the intra-tumor microenvironment, in particular by increasing the expression of PD-L1 on tumor cells. This action might potentially enhance available treatments with a modest increase in toxicity.
- || iniparib (BSI 201) / Sanofi
Clinical, P2 data, Journal: Phase II Study of Iniparib with Concurrent Chemoradiation in Patients with Newly Diagnosed Glioblastoma. (Pubmed Central) - Feb 29, 2020
The primary objective of improved mOS compared with historical a control was met, indicating potential antitumor activity of iniparib in this setting. Dosing optimization (frequency and sequence) is needed prior to additional efficacy studies.
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Retrospective data, Journal, BRCA Biomarker, PARP Biomarker: A Bayesian network meta-analysis of the efficacy of targeted therapies and chemotherapy for treatment of triple-negative breast cancer. (Pubmed Central) - Feb 20, 2020
In conclusion, our results indicated that the addition of bevacizumab to CT was beneficial for TNBC patients, and olaparib had a great effect in PFS and ORR, especially for those with BRCA mutations. When combined with CT, targeted agents including iniparib, sorafenib, cetuximab, and ipatasertib may have better efficacies for treating TNBC.
- || carboplatin / Generic mfg., iniparib (BSI 201) / Sanofi, gemcitabine / Generic mfg.
Clinical, P2 data, PK/PD data, Journal, Combination therapy: Iniparib administered weekly or twice-weekly in combination with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: a phase II randomized open-label study with pharmacokinetics. (Pubmed Central) - Jan 11, 2020
P2
When combined with CT, targeted agents including iniparib, sorafenib, cetuximab, and ipatasertib may have better efficacies for treating TNBC. Despite a doubled maximum concentration with weekly iniparib, no detectable differences in safety or efficacy were observed between the weekly and twice-weekly administration schedules in this population.
- |||| iniparib (BSI 201) / Sanofi
@hoperugo explained current crop of breast cancer PARP inhibitors was slowed after 2009 failure of Iniparib, the PARP inhibitor that turned out not to be PARP inhibitor #LSBC19 See https://t.co/W2RbL6bQJO (Twitter) - Oct 5, 2019
- | veliparib (ABT-888) / AbbVie, iniparib (BSI 201) / Sanofi, Lynparza (olaparib) / Merck (MSD), AstraZeneca
Journal, PARP Biomarker: Enhancement of Soft Tissue Sarcoma Cell Radiosensitivity by Poly(ADP-ribose) Polymerase-1 Inhibitors. (Pubmed Central) - Apr 7, 2019
In conclusion, we have shown that PARPi are potent radiosensitizers of human STS cells. These results support the pursuit of further investigations into the effects of PARPi combined with radiation on STS.
- | iniparib (BSI 201) / Sanofi
Clinical, Journal: Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple Negative Breast Cancer. (Pubmed Central) - Jan 14, 2018
HR deficiency identifies TNBC tumors, including BRCA1/2 nonmutated tumors more likely to respond to platinum-containing therapy. Clin Cancer Res; 22(15); 3764-73.
- | iniparib (BSI 201) / Sanofi, Lynparza (olaparib) / Merck (MSD), AstraZeneca
Journal: PET of Poly (ADP-Ribose) Polymerase Activity in Cancer: Preclinical Assessment and First In-Human Studies. (Pubmed Central) - May 24, 2017
The area under the receiver operating characteristic curve (AUC, in g/mL· min) for (18)F-FTT was assessed in normal mouse organs before and after treatment with olaparib (n = 14), a PARP inhibitor, or iniparib (n = 11), which has no PARP inhibitory activity. Conclusion The results suggest that (18)F-FTT uptake reflects PARP expression and that its radiation dosimetry profile is compatible with those of agents currently in clinical use.
- |||| iniparib (BSI 201) / Sanofi
Trial completion, Combination therapy, PARP Biomarker: SOLTI NEOPARP: Two Regimens of SAR240550/Weekly Paclitaxel and Paclitaxel Alone as Neoadjuvant Therapy in Triple Negative Breast Cancer Patients (clinicaltrials.gov) - Mar 22, 2017
P2, N=141, Completed, Sponsor: Sanofi
Conclusion The results suggest that (18)F-FTT uptake reflects PARP expression and that its radiation dosimetry profile is compatible with those of agents currently in clinical use. Active, not recruiting --> Completed
- || iniparib (BSI 201) / Sanofi
Trial completion, Enrollment change, Monotherapy: Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial (clinicaltrials.gov) - Oct 4, 2016
P3, N=37, Completed, Sponsor: Sanofi
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=300 --> 37
- |||| iniparib (BSI 201) / Sanofi
Trial primary completion date, Monotherapy: Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial (clinicaltrials.gov) - Jun 22, 2016
P3, N=300, Active, not recruiting, Sponsor: Sanofi
Active, not recruiting --> Completed | N=300 --> 37 Trial primary completion date: Jun 2016 --> Sep 2016
- || iniparib (BSI 201) / Sanofi
Trial primary completion date, Combination therapy, PARP Biomarker, Metastases: A Study Evaluating BSI-201 in Combination With Chemotherapeutic Regimens in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Jun 11, 2016
P1b, N=136, Completed, Sponsor: Sanofi
Trial primary completion date: Jun 2016 --> Sep 2016 Trial primary completion date: Nov 2010 --> Jan 2009
- |||| iniparib (BSI 201) / Sanofi
Trial primary completion date, Monotherapy: Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial (clinicaltrials.gov) - Jan 17, 2016
P3, N=300, Active, not recruiting, Sponsor: Sanofi
Trial primary completion date: Nov 2010 --> Jan 2009 Trial primary completion date: Dec 2015 --> Jun 2016
- |||| iniparib (BSI 201) / Sanofi
Trial completion: Study of the Poly (ADP-ribose) Polymerase-1 (PARP-1) Inhibitor BSI-201 in Patients With Newly Diagnosed Malignant Glioma (clinicaltrials.gov) - Jul 13, 2015
P1/2, N=126, Completed, Sponsor: Sanofi
Trial primary completion date: Dec 2015 --> Jun 2016 Active, not recruiting --> Completed
- iniparib (BSI 201) / Sanofi
Trial primary completion date: RAPIBE: A Trial Evaluating Concurrent Whole Brain Radiotherapy and Iniparib in Multiple Non Operable Brain Metastases (clinicaltrials.gov) - Mar 7, 2015
P1, N=3, Terminated, Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle
Active, not recruiting --> Completed Trial primary completion date: Dec 2014 --> Feb 2014
- iniparib (BSI 201) / Sanofi
Enrollment change, Trial termination: RAPIBE: A Trial Evaluating Concurrent Whole Brain Radiotherapy and Iniparib in Multiple Non Operable Brain Metastases (clinicaltrials.gov) - Feb 20, 2015
P1, N=3, Terminated, Sponsor: Centre Val d'Aurelle - Paul Lamarque
Trial primary completion date: Dec 2014 --> Feb 2014 N=30 --> 3 | Recruiting --> Terminated; end of study of this product
- ||||| iniparib (BSI 201) / Sanofi
Enrollment closed, Enrollment change, Trial primary completion date, Monotherapy: Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial (clinicaltrials.gov) - Oct 23, 2014
P3, N=300, Active, not recruiting, Sponsor: Sanofi
N=30 --> 3 | Recruiting --> Terminated; end of study of this product Recruiting --> Active, not recruiting | N=41 --> 300 | Trial primary completion date: Jun 2014 --> Dec 2015
- || iniparib (BSI 201) / Sanofi
Trial primary completion date: Study of the Poly (ADP-ribose) Polymerase-1 (PARP-1) Inhibitor BSI-201 in Patients With Newly Diagnosed Malignant Glioma (clinicaltrials.gov) - Oct 22, 2014
P1/2, N=120, Active, not recruiting, Sponsor: Sanofi
Recruiting --> Active, not recruiting | N=41 --> 300 | Trial primary completion date: Jun 2014 --> Dec 2015 Trial primary completion date: Dec 2013 --> Dec 2014
- ||| iniparib (BSI 201) / Sanofi
Trial completion, Enrollment change, Combination therapy, PARP Biomarker: A Dose Escalation Study of Iniparib as a Single Agent and in Combination in Solid Tumors (clinicaltrials.gov) - Oct 22, 2014
P1, N=59, Completed, Sponsor: Sanofi
Trial primary completion date: Dec 2013 --> Dec 2014 Active, not recruiting --> Completed | N=160 --> 59
- | iniparib (BSI 201) / Sanofi
Trial completion, Combination therapy: A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis (clinicaltrials.gov) - Oct 22, 2014
P2, N=44, Completed, Sponsor: Sanofi
Active, not recruiting --> Completed | N=160 --> 59 Active, not recruiting --> Completed
- ||| iniparib (BSI 201) / Sanofi
Enrollment closed: Study of the Poly (ADP-ribose) Polymerase-1 (PARP-1) Inhibitor BSI-201 in Patients With Newly Diagnosed Malignant Glioma (clinicaltrials.gov) - Oct 16, 2013
P1/2, N=120, Active, not recruiting, Sponsor: Sanofi
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | iniparib (BSI 201) / Sanofi
Enrollment change, Monotherapy: Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial (clinicaltrials.gov) - Sep 13, 2013
P3, N=41, Recruiting, Sponsor: Sanofi
Recruiting --> Active, not recruiting N=300 --> 41
- || iniparib (BSI 201) / Sanofi
Enrollment closed, Combination therapy, PARP Biomarker: A Dose Escalation Study of Iniparib as a Single Agent and in Combination in Solid Tumors (clinicaltrials.gov) - Sep 13, 2013
P1, N=160, Active, not recruiting, Sponsor: Sanofi
N=300 --> 41 Recruiting --> Active, not recruiting
- ||||||| iniparib (BSI 201) / Sanofi
Trial completion, Metastases: ECLIPSE: Trial of Gemcitabine/Carboplatin With or Without Iniparib (SAR240550) (a PARP1 Inhibitor) in Subjects With Previously Untreated Stage IV Squamous Non-Small-Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Sep 13, 2013
P3, N=780, Completed, Sponsor: Sanofi
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- |||| iniparib (BSI 201) / Sanofi
Trial completion, PARP Biomarker: A Phase 2 Study of Standard Chemotherapy Plus BSI-201 (a PARP Inhibitor) in the Neoadjuvant Treatment of Triple Negative Breast Cancer (clinicaltrials.gov) - Sep 13, 2013
P2, N=80, Completed, Sponsor: Sanofi
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||| iniparib (BSI 201) / Sanofi
Trial completion, Combination therapy, Metastases: Study of SAR240550 (BSI-201) in Combination With Gemcitabine/Carboplatin, in Patients With Metastatic Triple Negative Breast Cancer (clinicaltrials.gov) - Jun 16, 2013
P2, N=163, Completed, Sponsor: Sanofi
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | iniparib (BSI 201) / Sanofi
Trial completion, PARP Biomarker, Metastases: Safety and Pharmacokinetics of SAR240550 (BSI-201) Twice Weekly in Patients With Advanced Solid Tumors (clinicaltrials.gov) - May 22, 2013
P1, N=18, Completed, Sponsor: Sanofi
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | iniparib (BSI 201) / Sanofi
Trial completion, Combination therapy, PARP Biomarker: A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Resistant Recurrent Ovarian Cancer (clinicaltrials.gov) - May 13, 2013
P2, N=43, Completed, Sponsor: Sanofi
Active, not recruiting --> Completed Active, not recruiting --> Completed
- iniparib (BSI 201) / Sanofi
Trial initiation date: RAPIBE: A Trial Evaluating Concurrent Whole Brain Radiotherapy and Iniparib in Multiple Non Operable Brain Metastases (clinicaltrials.gov) - Oct 17, 2012
P1, N=30, Recruiting, Sponsor: Centre Val d'Aurelle - Paul Lamarque
Active, not recruiting --> Completed Initiation date: Mar 2012 --> Sep 2012
- iniparib (BSI 201) / Sanofi
Enrollment open: RAPIBE: A Trial Evaluating Concurrent Whole Brain Radiotherapy and Iniparib in Multiple Non Operable Brain Metastases (clinicaltrials.gov) - Oct 17, 2012
P1, N=30, Recruiting, Sponsor: Centre Val d'Aurelle - Paul Lamarque
Initiation date: Mar 2012 --> Sep 2012 Not yet recruiting --> Recruiting
- | iniparib (BSI 201) / Sanofi
Enrollment closed, Combination therapy: A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis (clinicaltrials.gov) - Aug 1, 2012
P2, N=40, Active, not recruiting, Sponsor: Sanofi
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | iniparib (BSI 201) / Sanofi
Trial completion, Combination therapy, PARP Biomarker: A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Sensitive Recurrent Ovarian Cancer (clinicaltrials.gov) - Jul 31, 2012
P2, N=41, Completed, Sponsor: Sanofi
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||| iniparib (BSI 201) / Sanofi
Enrollment change, PARP Biomarker: A Phase 2 Study of Standard Chemotherapy Plus BSI-201 (a PARP Inhibitor) in the Neoadjuvant Treatment of Triple Negative Breast Cancer (clinicaltrials.gov) - Jun 3, 2012
P2, N=80, Completed, Sponsor: Sanofi
Active, not recruiting --> Completed N=36 --> 80
- | iniparib (BSI 201) / Sanofi
Enrollment change, Metastases: Single Arm Study of BSI-201 in Patients With BRCA-1 or BRCA-2 Associated Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov) - Jun 3, 2012
P2, N=12, Completed, Sponsor: Sanofi
N=36 --> 80 N=35 --> 12
- ||| iniparib (BSI 201) / Sanofi
Enrollment change: Study of the Poly (ADP-ribose) Polymerase-1 (PARP-1) Inhibitor BSI-201 in Patients With Newly Diagnosed Malignant Glioma (clinicaltrials.gov) - May 23, 2012
P1/2, N=120, Active, not recruiting, Sponsor: Sanofi
N=35 --> 12 N=100 --> 120
- | iniparib (BSI 201) / Sanofi
Enrollment change, PARP Biomarker, Metastases: Evaluation of Paclitaxel (Taxol, NSC #673089), Carboplatin (Paraplatin, NSC #241240), and BSI-201 (NSC #746045, IND #71,677) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma (clinicaltrials.gov) - May 22, 2012
P2, N=22, Completed, Sponsor: Sanofi
N=100 --> 120 N=45 --> 22